Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

The International Journal of Surgical Oncology, published by HINDAWI LTD, stands as a pivotal resource within the realms of surgical and oncology research, with a commendable impact on the field since its inception. Established as an Open Access journal in 2010, it facilitates the dissemination of high-quality, peer-reviewed research that is accessible to a global audience, ensuring that the latest advancements in surgical techniques and oncology treatments reach researchers, practitioners, and students alike. With its current standings of Q3 in Oncology and Q2 in Surgery, alongside impressive Scopus rankings—150/551 in Medicine _ Surgery and 224/404 in Medicine _ Oncology—the journal is recognized for its influential contributions to these critical medical fields. Covering a wide array of topics from innovative surgical methods to comprehensive cancer care approaches, the journal aims to foster collaboration and knowledge-sharing among professionals seeking to enhance patient outcomes across diverse surgical oncology practices. With continued convergence of research from 2012 to 2024, the journal remains at the forefront of addressing contemporary challenges faced in surgical oncology today.

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

npj Breast Cancer, published by NATURE PORTFOLIO, stands at the forefront of breast cancer research as an esteemed open access journal since 2015. With its impressive trajectory, the journal has garnered a notable impact within the academic community, reflecting a Q1 ranking in prestigious categories such as Oncology, Pharmacology, and Radiology for 2023. Based in the United Kingdom and indexed under E-ISSN 2374-4677, npj Breast Cancer aims to disseminate cutting-edge research that fosters innovation in prevention, diagnosis, and treatment of breast cancer, thereby addressing one of the most pressing health issues of our time. Its placement within Scopus rankings, including a remarkable 19th position in Pharmacology and a percentile ranking in the 90th range for Radiology and Oncology, highlights its significance as a key resource for researchers, healthcare professionals, and policy-makers dedicated to advancing cancer care. Emphasizing accessibility and high-quality content, npj Breast Cancer provides an influential platform for interdisciplinary collaboration and discovery in the ongoing battle against breast cancer.